Insider Selling: Artivion (NYSE:AORT) CEO Sells $2,026,500.00 in Stock
Artivion's CEO, James Mackin, sold 70,000 shares of company stock for $2.03 million, reducing his ownership by 7.39%. This transaction follows the company's recent earnings report where it exceeded revenue expectations with $125.76 million. Despite the insider selling, analysts maintain a "Moderate Buy" rating for AORT, with an average price target of $44.83.
Does Revenue Growth Amid New Losses Reshape The Bull Case For Artivion (AORT)?
Artivion, Inc. reported increased revenue for Q2 2026 and H1 2026, but also experienced a swing from net income to net losses. This shift raises questions about the company's ability to convert revenue growth into sustainable profits, despite the recent FDA approval for its AMDS product, which represents a significant market opportunity. The article suggests investors consider multiple future scenarios for Artivion, given its growing debt and recent unprofitability.
Artivion (NASDAQ: AORT) executive moves to sell 70,000 shares
Artivion (NASDAQ: AORT) officer James P. Mackin has filed a Form 144 notice to sell up to 70,000 shares of common stock, with an aggregate market value of $2,053,100.00. The shares, originally compensation for services, are intended to be sold through Fidelity Investments on the NYSE. The filing indicates a neutral impact and sentiment on the company's stock.
Summit Creek Advisors LLC Takes Position in Artivion, Inc. $AORT
Summit Creek Advisors LLC has acquired a new stake of 120,354 shares in Artivion, Inc. worth approximately $2.7 million, representing a 0.25% ownership. Institutional investors and hedge funds now collectively own 86.37% of the company, which maintains a "Moderate Buy" consensus rating from analysts with an average price target of $44.83. Artivion recently exceeded revenue expectations, reporting $125.76 million against an estimate of $119.99 million, and earnings of $0.13 per share.
Canaccord raises Artivion stock price target to $40 on model update
Canaccord Genuity has increased its price target for Artivion Inc. (NYSE:AORT) to $40 from $39, maintaining a Buy rating. This adjustment follows a model update reflecting additional data from the company's Q2 10-Q filing and a change in the comparable company group multiple. Artivion recently reported strong Q2 revenues and adjusted EBITDA, exceeding analyst forecasts, and has received PMA approval for AMDS and completed the acquisition of Endospan.
Artivion SVP Andrew Green sells $17,586 of common stock
Artivion (AORT) SVP Andrew M. Green sold $17,586 worth of common stock on August 14, 2026, consisting of 616 shares at $28.549 each. This was a non-discretionary transaction to cover tax withholding obligations from vested restricted stock units. Following the sale, Green directly holds 59,643 shares, while the company has recently reported strong Q2 earnings, exceeding analyst forecasts, and received a raised price target from Canaccord.
Artivion EVP, COO, CFO & treasurer Berry sells $20,412 in stock
Lance A. Berry, EVP, COO, CFO, and Treasurer of Artivion, Inc. (NASDAQ:AORT), sold 715 shares of common stock for $20,412 on August 14, 2026, to cover tax withholding obligations. This transaction is considered a "sell to cover" and not a discretionary sale, with Berry retaining 210,112 shares. Artivion recently reported strong Q2 2026 revenue of $125.8 million, surpassing forecasts, and Canaccord raised its price target for the company to $39.
Artivion EVP, COO, CFO & treasurer Berry sells $20,412 in stock
Lance A. Berry, EVP, COO, CFO, and Treasurer of ARTIVION, INC. (NASDAQ:AORT), sold 715 shares of common stock totaling $20,412 on August 14, 2026, to cover tax withholding obligations. Following the transaction, Berry directly holds 210,112 shares. Separately, Artivion reported strong Q2 revenue and adjusted EBITDA, surpassing analyst expectations, and received a raised price target from Canaccord.
Artivion CFO Lance A. Berry Sells 715 Shares to Cover RSU Tax Withholding
Artivion's CFO, Lance A. Berry, sold 715 shares of the company's common stock on August 14, 2026, at $28.549 per share. This transaction was not discretionary but was executed as a "sell to cover" to meet tax withholding obligations arising from the vesting of restricted stock units. Following this sale, Berry directly holds 210,112 shares of Artivion common stock.
Artivion SVP Andrew Green sells $17,586 of common stock
Andrew M. Green, SVP of Regulatory and Quality at ARTIVION, INC. (AORT), sold 616 shares of common stock totaling $17,586 on August 14, 2026, to cover tax withholding obligations. This non-discretionary sale occurred while ARTIVION shares showed an 11% return over the past week. The company also reported strong Q2 revenues, exceeding forecasts, and maintained its fiscal 2026 guidance, receiving a raised price target from Canaccord.
Artivion (NYSE: AORT) exec’s 616-share sale is tax-driven
Artivion executive Andrew M. Green, SVP, Regulatory and Quality, sold 616 shares of common stock at $28.549 per share on August 14, 2026. This transaction was a "sell to cover" to satisfy tax withholding obligations upon the vesting of restricted stock units and was not a discretionary trade. Following the sale, Green directly holds 59,643 shares of ARTIVION common stock.
Artivion (NYSE:AORT) Rating Lowered to Sell at Wall Street Zen
Wall Street Zen has downgraded Artivion (NYSE:AORT) from "hold" to "sell," though other analysts maintain a "Moderate Buy" consensus with an average target price of $44.67. The company recently exceeded revenue estimates, reporting $125.76 million against a $119.99 million consensus, with quarterly EPS of $0.13. Artivion's stock opened at $29.22, and recent insider transactions show share sales by senior vice presidents.
ARTIVION, INC. SEC Filing (Aug 14, 2026)
This article details an SEC Form 144 filing by Artivion, Inc. (AORT) on August 14, 2026, which indicates a proposed sale of 715 shares of common stock acquired through restricted stock vesting. The filing was accepted by the SEC at 3:59 PM on the same date and outlines the transaction details including the broker, market value, and date of acquisition.
Artivion (AORT): Nomura entities report 6.5% beneficial stake in 13G/A
Nomura Asset Management International Inc. and Nomura Investment Management Business Trust have reported a combined 6.5% beneficial ownership in Artivion, Inc., totaling 3,184,974 shares of common stock. This filing, a Schedule 13G/A, indicates shared voting and dispositive power over these shares, calculated based on 48,692,000 outstanding shares as of June 30, 2026. The report emphasizes transparency regarding significant ownership stakes in publicly traded companies.
Artivion SVP Jean Holloway sells 977 shares for $27,834
Artivion's Senior Vice President, Jean F. Holloway, sold 977 shares of company stock for $27,834, with each share priced at $28.49. This transaction leaves her with 184,118 directly held shares. Despite the stock appearing overvalued according to InvestingPro, analysts maintain price targets between $38 and $48, and the company recently reported strong Q2 revenues and raised guidance.
Artivion (AORT) Is Up 5.5% After FDA AMDS Approval And Reaffirmed 2026 Revenue Guidance - What's Changed
Artivion (AORT) shares rose 5.5% following FDA approval for its AMDS hybrid prosthesis and reaffirmed 2026 revenue guidance of approximately US$488 million. Despite a recent shift to a net loss from a net income in Q2 2026, the company's revenue outperformance and strategic product additions like AMDS and the NEXUS system are key drivers for its future growth. The FDA approval of AMDS is particularly significant as it targets an estimated US$150 million U.S. market and is central to the company's current catalyst stack, potentially influencing product mix and margin potential.
Artivion SVP Jean Holloway sells 977 shares for $27,834
Jean F. Holloway, SVP at Artivion Inc. (NASDAQ:AORT), sold 977 shares for $27,834 at $28.49 per share. This transaction occurred after the stock saw a 9.4% gain over the past week, and Holloway now directly holds 184,118 shares. The company recently reported strong Q2 revenue and adjusted EBITDA, leading Canaccord to raise its price target to $39.
Jean Holloway Sells 977 Shares of Artivion (NYSE:AORT) Stock
Jean Holloway, SVP of Artivion (NYSE:AORT), sold 977 shares of the company's stock for a total of $27,834.73, reducing her direct ownership to 184,118 shares. This transaction occurred as Artivion reported strong quarterly earnings, exceeding revenue estimates, and maintains a "Moderate Buy" consensus rating from analysts.
Artivion (AORT) Is Up 5.5% After FDA AMDS Approval And Reaffirmed 2026 Revenue Guidance - What's Changed
Artivion (AORT) stock rose by 5.5% following FDA approval for its AMDS hybrid prosthesis and the reaffirmation of its 2026 revenue guidance. The company reported increased revenue but a shift to a net loss in Q2 2026. This approval for AMDS is considered a key catalyst for Artivion, aiming to drive revenue growth and potentially narrow losses, despite short-term earnings volatility and reliance on complex, high-priced devices.
Artivion, Inc. (AORT) Stock Analysis: Strong Buy Ratings Signal Potential Upside of Nearly 60%
Artivion, Inc. (AORT), a healthcare sector player specializing in medical devices and implantable human tissues, shows promising growth potential despite recent market fluctuations. Analysts have given it strong "Buy" ratings with an average target price of $42.03, suggesting a nearly 60% upside from its current trading price of $26.31. While the company has areas for improvement in profitability metrics, its impressive revenue growth, healthy free cash flow, and strategic market positioning make it an intriguing opportunity for investors looking for long-term growth.
Artivion (AORT) Revenue Rose As Losses Emerged, Is It Still 37% Below Fair Value?
Artivion (AORT) recently reported Q2 2026 results showing increased revenue but a shift to losses. Despite a year-to-date share price decline, the company's valuation narrative suggests it is 37.4% undervalued, with a fair value of $42. This undervaluation hinges on continued regulatory approvals, new product launches, and geographical expansion.
Artivion revenue up 11% to USD 125.8M in Q2 2026
Artivion, Inc. reported an 11% increase in total revenues to $125.8 million for Q2 2026, driven by strong growth in On-X and stent grafts. The company also announced the acquisition of Endospan Ltd. and U.S. FDA approval for its AMDS Hybrid Prosthesis, strengthening its aortic arch portfolio. Artivion is reiterating its full-year 2026 revenue guidance of $480 to $496 million and adjusted EBITDA of $92 to $99 million.
Artivion (AORT) Stock Can Revenue Growth Outrun Fresh Losses?
Artivion (AORT) saw its stock edge up slightly despite a mixed Q2 2026 earnings report, which showed strong revenue growth but a swing back to a net loss. The company's aortic franchise, particularly with AMDS approval and growth in On X valves, fuels the bull case, while bears focus on margin compression, negative free cash flow, and execution risks from increased spending. Investors are weighing the potential for revenue growth against the immediate profitability challenges.
Canaccord raises Artivion stock price target on acquisition, PMA approval
Canaccord raised its price target for Artivion Inc. (NYSE:AORT) to $39 from $36, maintaining a Buy rating, following the company's acquisition of Endospan and PMA approval for AMDS. Artivion's second-quarter revenue of $125.8 million and adjusted EBITDA of $26.4 million both surpassed analyst estimates, driven by strong growth in On-X and Aortic Stent Grafts. The company reiterated its fiscal 2026 guidance, with net income expected to grow and commercialization of the NEXUS product in the U.S. anticipated to begin in 2027.
ARTIVION, INC. 2026: Revenue $125.76M, EPS ($0.28) — 10-Q Summary
ARTIVION, INC. (AORT) reported its quarterly results for 2026, with revenue increasing by 11.3% year-over-year to $125.76M. Despite the revenue growth, the company recorded a net loss of ($13.51M) and diluted EPS of ($0.28), a significant decrease from the prior year's net income. Key drivers for revenue growth included aortic stent grafts, On-X products, and preservation services, along with strategic acquisitions and accelerated adoption of new medical devices.
Q2 2026 Artivion Inc Earnings Call Transcript
Artivion Inc. (NYSE: AORT) recently held its Q2 2026 earnings call, detailing strong performance including FDA approval for its AMDS hybrid prosthesis and the acquisition of Endospan. The company reported significant growth in stent graft and ONIX revenues, and reiterated its full-year 2026 guidance, expecting 7-11% constant currency revenue growth and $92-99 million in adjusted EBITDA, despite a decrease in adjusted EBITDA margin and negative free cash flow due to investments and acquisition costs. Management expressed confidence in future growth while acknowledging some challenges like the delayed US launch of Nexus and variability in BioGlue revenue.
Artivion, Inc. 2026 Q2 - Results - Earnings Call Presentation (NYSE:AORT) 2026-08-07
Artivion, Inc. (AORT) released its 2026 Q2 earnings call presentation. The company reported an EPS of $0.13, beating estimates by $0.03, and revenue of $125.76 million, an 11.32% year-over-year increase, beating estimates by $5.74 million. This article provides access to the slide deck published in conjunction with these results.
Is Artivion Inc (AORT) Undervalued Despite $125.8 Million Revenue in Q2? GF Score: 82/100
Artivion Inc (AORT) reported Q2 2026 revenues of $125.8 million, an 11% year-over-year increase, exceeding analyst estimates, yet posted a net loss of $13.5 million. Despite the loss, driven partly by foreign currency revaluation and increased operating expenses, the company strengthened its product portfolio with FDA approval and an acquisition. GuruFocus assesses AORT as undervalued with a GF Score of 82/100 and a 6.8% upside potential, noting strong growth but average financial strength and profitability.
Earnings Flash (AORT) Artivion, Inc. Posts Q2 Adjusted EPS $0.13 per Share, Vs. FactSet Est of $0.10
Artivion, Inc. (AORT) announced its Q2 adjusted EPS of $0.13 per share, surpassing the FactSet estimate of $0.10. This indicates a stronger financial performance than anticipated by analysts.
Artivion (AORT) Q2 Earnings Meet Estimates
Artivion (AORT) reported Q2 earnings of $0.13 per share, meeting the Zacks Consensus Estimate, though this is down from $0.24 a year ago. The company's revenues for the quarter were $125.76 million, surpassing estimates by 4.02%. Artivion's stock has underperformed the S&P 500 this year, and it currently holds a Zacks Rank #3 (Hold).
Artivion Q2 2026 slides: FDA wins fuel aortic arch expansion
Artivion Inc. reported strong Q2 2026 results, with 9% constant-currency revenue growth driven by stent grafts and On-X mechanical heart valves. The company achieved two major regulatory milestones: FDA PMA approval for the AMDS Hybrid Prosthesis and the completion of the Endospan acquisition following NEXUS Aortic Arch System approval. These regulatory successes position Artivion for significant expansion in the complex aortic arch market, despite near-term profitability impacts from acquisition-related expenses.
Artivion (NYSE:AORT) Delivers Strong Q2 CY2026 Numbers
Artivion (NYSE:AORT) reported strong Q2 CY2026 results, with revenue of $125.8 million, beating analyst estimates by 4.4%, and non-GAAP EPS of $0.13, exceeding estimates by 34.5%. The medical device company reconfirmed its full-year revenue guidance and provided optimistic EBITDA guidance. Despite a decrease in operating margin and free cash flow year-on-year, the company's long-term revenue growth remains healthy, although EPS growth has been impacted by shareholder dilution.
Earnings Flash (AORT) Artivion, Inc. Reports Q2 Revenue $125.8M, vs. FactSet Est of $120.0M
Artivion, Inc. (AORT) has reported its Q2 revenue of $125.8 million, surpassing FactSet's estimate of $120.0 million. This earnings flash indicates a positive financial performance for the medical device company. The news was published on August 6, 2026, at 05:07 pm EDT.
Artivion: Q2 Earnings Snapshot
Artivion, Inc. (AORT) reported a second-quarter loss of $13.5 million, or 28 cents per share, which contrasts with a profit in the same period last year. Adjusted earnings for the biological medical device maker were 13 cents per share, with revenue reaching $130.8 million. The company forecasts full-year revenue between $500 million and $530 million, while its shares have declined 22% year-to-date and 18% over the last 12 months.
Artivion Reports Second Quarter 2026 Financial Results
Artivion, Inc. announced strong financial results for the second quarter of 2026, with revenue increasing 11% on a GAAP basis and 9% on a constant currency basis. The company reported adjusted EBITDA growth of 7% and highlighted key achievements including the acquisition of Endospan Ltd. and U.S. FDA PMA approval for its AMDS Hybrid Prosthesis, strengthening its aortic arch product portfolio. Artivion reiterated its full-year 2026 revenue and adjusted EBITDA guidance.
Artivion earnings on deck: Can FDA approval revive growth? By Investing.com
Artivion Inc. is set to report its second-quarter earnings, with investors focusing on whether its recent FDA premarket approval for the AMDS Hybrid Prosthesis can counteract slowing sales and revive growth. Despite a 46% drop in shares from their 52-week high and a sequential decline in outlook, all eight analysts covering the stock rate it a buy, anticipating a major product cycle from AMDS and the NEXUS Aortic Arch System to drive revenue and EBITDA growth. Key concerns include the pace of AMDS adoption post-FDA approval and the company's full-year guidance, which was lowered after a disappointing first quarter.
FMR LLC, Abigail Johnson report 4.0% Artivion Inc (AORT) ownership in 13G/A
FMR LLC and Abigail P. Johnson have filed a Schedule 13G/A, reporting a 4.0% beneficial ownership stake in Artivion Inc (AORT). As of June 30, 2026, they collectively beneficially own 1,963,471.40 shares, with FMR LLC holding sole voting power over 1,962,433.00 shares and sole dispositive power over 1,963,471.40 shares. The filing indicates that while other persons may receive dividends or sale proceeds, no single other person holds more than five percent of Artivion Inc's outstanding common stock through these holdings.
How AMDS Launch Momentum and Capital Discipline Could Reframe Artivion’s (AORT) Growth-Risk Balance
Artivion (AORT), formerly CryoLife, is gaining attention due to the positive physician feedback and early clinical uptake of its AMDS aortic device in the U.S. This new product and focus on capital efficiency could significantly impact the company's growth and operational strategy. The article discusses how the AMDS launch might reshape Artivion's investment narrative, particularly concerning its potential to drive revenue and mitigate risks like pricing pressure.
Is Artivion (AORT) Undervalued As Investors Reassess Its Growth And Capital Efficiency?
Artivion (AORT) is being re-evaluated by investors due to its smaller revenue base, limited free cash flow, and capital efficiency challenges. Despite a 14.6% share price increase over the last month, the company has seen a 20.9% decline over 90 days. While some narratives suggest Artivion is 35% undervalued with a fair value of $42, its current P/E ratio of 114.2x significantly exceeds industry averages, indicating mixed sentiment and potential overvaluation.
Artivion, Inc. Revenue Breakdown – HAM:CYL
Artivion, Inc. (CYL) generated 375.76 million EUR in revenue last year. Its Medical Devices segment was the top performer, contributing 294.44 million EUR. The United States was the primary regional contributor, accounting for 182.27 million EUR of the total revenue.
Artivion Number of Employees 2026 | Employee Count & Headcount Data
Artivion, Inc. (AORT) had 1,828 employees worldwide as of March 2026, representing a 14.8% growth since 2023. The company is actively hiring with 107 job postings in 2026, and its workforce is primarily concentrated in North America (51.1%). The average salary at Artivion is $85,590, though it varies significantly by region.
Artivion Inc (AORT) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Artivion Inc (AORT), highlighting its volatility and financial risk. The company's risk assessment score is 8.23, ranking it 23 out of 199 in the Healthcare Equipment & Supplies industry. Key metrics such as beta, VaR, maximum drawdown, and volatility over various periods are detailed.
Artivion's August events include a Boston webcast and virtual meetings
Artivion (NYSE: AORT) announced its participation in two investor conferences in August 2026. Management will present at the Canaccord Genuity 46th Annual Growth Conference in Boston on August 12, 2026, with a live webcast available, and will hold investor meetings at the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on August 11, 2026, which will not have a webcast. The company, focused on cardiac and vascular surgery for aortic disease, provides detailed information on its investor relations page.
AORT|Artivion Inc|Price:26.100|Chg%:+0.820
Artivion, Inc. (AORT) is a medical device company specializing in solutions for cardiac and vascular surgeons treating aortic diseases, manufacturing and distributing medical devices and implantable human tissues. The company's main product families include aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable human tissues, with aortic stent grafts being its largest revenue source. As of Q1 2026, 449 institutions hold shares of Artivion Inc, representing 93.40% of total shares.
Artivion Inc (AORT) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Artivion Inc (AORT), listing its major shareholders and their respective proportions, including BlackRock Institutional Trust Company, N.A., Nomura Investment Management Business Trust, and Fidelity Management & Research Company LLC. It also provides a breakdown of shareholder types, institutional shareholding trends over several quarters, and major shareholder activity with changes in holdings. Additionally, it lists various ETFs that include AORT in their portfolios.
Artivion, Inc. Revenue Breakdown – SWB:CYL
Artivion, Inc. (SWB:CYL) generated a total revenue of 375.76 M EUR last year. The Medical Devices segment was the top-performing segment, contributing 294.44 M EUR, an increase from the previous year. The United States was the largest regional contributor to the company's revenue, accounting for 182.27 M EUR.
AORT|Artivion Inc|Price:25.280|Chg%:+0.280
Artivion Inc (AORT) is trading at 25.280 USD, up 1.12% with a market cap of 1.23 billion. The company, which specializes in medical devices for aortic diseases, shows healthy fundamentals and high growth potential, though its valuation is considered fairly valued within its industry. Analysts rate it as a "Buy" with a target price of 42.00, despite a projected medium-term downtrend and technical indicators suggesting sideways trading.
Artivion, Inc. Revenue Breakdown – LS:900006
Artivion, Inc. generated 375.76 million EUR in revenue last year, with its Medical Devices segment being the top-performer, bringing in 294.44 million EUR. The United States was the largest geographical contributor, accounting for 182.27 million EUR of the company's revenue. This financial breakdown provides insight into the company's key revenue drivers and regional performance.
Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2026 Financial Results
Artivion, Inc. announced that its second quarter 2026 financial results will be released on Thursday, August 6, 2026, after the market closes. The company will host a teleconference call and live webcast at 4:30 p.m. ET on the same day to discuss the results, followed by a Q&A session. Details for accessing the live teleconference, replay, and webcast are provided for investors.
Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2026 Financial Results
Artivion, Inc. (AORT) will release its second-quarter 2026 financial results on Thursday, August 6, 2026, after the market closes. The company will host a teleconference call and webcast at 4:30 p.m. ET to discuss these results, followed by a Q&A session with Chairman, President, and CEO Pat Mackin. Investors can access the live webcast and replay, along with the earnings press release, on the Investors section of the Artivion website.
